Oslo, 17 August 2026: Reference is made to the stock exchange announcement
published by Aker BioMarine ASA (the "Company") on 16 July 2026 regarding the
announcement of a triangular merger pursuant to Chapter 13 of the Norwegian
Public Limited Liability Companies Act between Aker BioMarine ASA and Aker
Capital NewCo AS ("ACN"), with ACN as the surviving legal entity (the "Merger"),
together with a related cash offer from Aker Capital AS to the shareholders of
the Company (the "Cash Offer"). Notice of an extraordinary general meeting to
approve the merger plan for the Merger was published on 17 July 2026.
The Company has today held the extraordinary general meeting. All items on the
agenda were resolved in accordance with the proposals from the Board of
Directors, including approval of the merger plan for the Merger. The minutes
from the extraordinary general meeting are attached hereto and are also
available on the Company's website www.akerbiomarine.com/AGM. The decision to
approve the Merger will be filed with the Norwegian Register of Business
Enterprises. Completion of the merger remains conditional upon customary closing
conditions as described in the merger plan.
Completion of the Cash Offer was conditional upon approval of the Merger by the
extraordinary general meeting in the Company. Settlement of the Cash Offer will
take place no later than three trading days after todays approval of the Merger
by the extraordinary general meeting in the Company.
For further information, please contact
Lars Jacobsen, General Counsel
Mobile: +47 906 05 306
Email: lars.jacobsen@akerbiomarine.com
This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.
he Norwegian Securities Trading Act.\